{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:45:09Z","timestamp":1776743109805,"version":"3.51.2"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.12.013","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:59:28Z","timestamp":1767891568000},"page":"191-199.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions: How Should We Risk Stratify and Tailor Therapy for Patients With High Tumor Burden Follicular Lymphoma? A Systematic Review"],"prefix":"10.1016","volume":"26","author":[{"given":"Neha","family":"Akkad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.12.013_bib0001","unstructured":"SEER Cancer Stat Facts: Follicular Lymphoma. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, Bethesda, MD. https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html"},{"issue":"26","key":"10.1016\/j.clml.2025.12.013_bib0002","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.12.013_bib0003","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"10.1016\/j.clml.2025.12.013_bib0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.12.013_bib0006","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17045","article-title":"Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"192","author":"Moccia","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.013_bib0007","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3324\/haematol.2018.209932","article-title":"Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial","volume":"104","author":"Bruna","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2025.12.013_bib0008","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0009","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.013_bib0010","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2025-1008","article-title":"Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL","volume":"146","author":"Grieve","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.013_bib0011","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1182\/blood-2022-162114","article-title":"FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort","volume":"140","author":"St-Pierre","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.12.013_bib0012","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0013","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2025.12.013_bib0014","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/hon.2922","article-title":"Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation","volume":"39","author":"Mozas","year":"2021","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.12.013_bib0017","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0018","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2025.12.013_bib0019","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1182\/bloodadvances.2020002546","article-title":"Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models","volume":"4","author":"Alig","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.12.013_bib0021","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","article-title":"International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline (18)F-FDG PET\/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation","volume":"65","author":"Boellaard","year":"2024","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0022","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.27711","article-title":"Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial","volume":"100","author":"Durmo","year":"2025","journal-title":"Am J Hematol"},{"issue":"30","key":"10.1016\/j.clml.2025.12.013_bib0023","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.013_bib0024","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study","volume":"132","author":"Barrington","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.annonc.2023.10.121","article-title":"Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial","volume":"35","author":"Cottereau","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0026","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0027","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0028","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1038\/bcj.2017.70","article-title":"Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma","volume":"7","author":"Tracy","year":"2017","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.clml.2025.12.013_bib0029","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102959","article-title":"Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial","volume":"78","author":"Friedberg","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.clml.2025.12.013_bib0031","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/10428194.2016.1196815","article-title":"FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study","volume":"58","author":"Kostakoglu","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2025.12.013_bib0032","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1007\/s00259-024-06765-z","article-title":"End of induction [(18)F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial","volume":"51","author":"Guerra","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.clml.2025.12.013_bib0033","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2024014790","article-title":"Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi","volume":"9","author":"Durmo","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.12.013_bib0034","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12185-024-03738-8","article-title":"End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial","volume":"119","author":"Kato","year":"2024","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.12.013_bib0035","doi-asserted-by":"crossref","first-page":"e3272","DOI":"10.1002\/hon.3272","volume":"42","author":"Watanabe","year":"2024","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.013_bib0036","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00277-022-04914-8","article-title":"Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis","volume":"101","author":"Gao","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.12.013_bib0037","article-title":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma","author":"Maurer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0038","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clml.2022.09.003","article-title":"Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study","volume":"23","author":"Casulo","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"10.1016\/j.clml.2025.12.013_bib0039","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","article-title":"Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study","volume":"135","author":"Mir","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.12.013_bib0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2601","article-title":"Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group","volume":"37","author":"M\u00e9ndez","year":"2019","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0041","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.12.013_bib0042","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0043","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hon.3184","article-title":"Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment na\u00efve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi","volume":"41","author":"Nizzoli","year":"2023","journal-title":"Hematological Oncology"},{"issue":"13","key":"10.1016\/j.clml.2025.12.013_bib0044","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.2009.25.0852","article-title":"BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0045","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.12.013_bib0046","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"},{"issue":"9759","key":"10.1016\/j.clml.2025.12.013_bib0047","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0048","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0049","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.23.01912","article-title":"Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low\u2013Tumor Burden Follicular Lymphoma","volume":"42","author":"Kahl","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1016\/j.clml.2025.12.013_bib0050","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0051","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/10428194.2013.790544","volume":"55","author":"Provencio","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0052","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2809","article-title":"Consolidation with (90) Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma","volume":"39","author":"Miura","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0053","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0609.2010.01445.x","article-title":"Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy","volume":"85","author":"McClanahan","year":"2010","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0054","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/bloodadvances.2024014053","article-title":"Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium","volume":"9","author":"Day","year":"2025","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.clml.2025.12.013_bib0055","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.clml.2025.12.013_bib0056","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0057","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2025.12.013_bib0058","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0059","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0060","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.bbmt.2016.04.014","article-title":"Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"22","author":"Laport","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0061","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0062","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0063","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"6","key":"10.1016\/j.clml.2025.12.013_bib0064","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2025.12.013_bib0065","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0066","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/j.clml.2025.12.013_bib0067","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.clml.2025.12.013_bib0068","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.12.013_bib0069","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0070","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2025.12.013_bib0071","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jjco\/hyaa153","article-title":"Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed\/refractory follicular lymphoma and chronic lymphocytic leukemia","volume":"50","author":"Fukuhara","year":"2020","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.12.013_bib0072","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.19994","article-title":"A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study","volume":"206","author":"Munakata","year":"2025","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.12.013_bib0073","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0074","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jjco\/hyaa169","article-title":"Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study","volume":"51","author":"Kinoshita","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0075","first-page":"1194","article-title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma: a phase Ib\/II study","volume":"109","author":"Flowers","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.12.013_bib0076","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ajh.27341","article-title":"Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"99","author":"Yuen","year":"2024","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clml.2025.12.013_bib0077","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.clml.2025.12.013_bib0078","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.12.013_bib0079","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0080","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.12.013_bib0081","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study ofvorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0082","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000449052","article-title":"A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up","volume":"137","author":"Bari","year":"2017","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.12.013_bib0083","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.12991","article-title":"Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma","volume":"166","author":"Craig","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.013_bib0084","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.12.013_bib0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","article-title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","volume":"12","author":"Coiffier","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.013_bib0086","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0087","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0088","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clml.2014.02.010","article-title":"Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma","volume":"14","author":"Hainsworth","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0089","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3026(15)00026-5","article-title":"Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b\/2 randomised study","volume":"2","author":"Cheah","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.013_bib0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cam4.4422","article-title":"Identification of a genetic signature enriching for response to ibrutinib in relapsed\/refractory follicular lymphoma in the DAWN phase 2 trial","volume":"11","author":"Balasubramanian","year":"2022","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.clml.2025.12.013_bib0091","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ijlh.13216","article-title":"Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma","volume":"42","author":"Shimono","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.013_bib0092","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2022-157194","article-title":"FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma","volume":"140","author":"Maurer","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:18:35Z","timestamp":1776741515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025043083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025043083"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: How Should We Risk Stratify and Tailor Therapy for Patients With High Tumor Burden Follicular Lymphoma? A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}